Octreotide Microspheres for Injection in Treating Patients with Primary Advanced Hepatocellular Carcinoma
SHAO Li-hua,LIU Yan,QIN Xiang-rong,ZHANG Wei
DOI: https://doi.org/10.3969/j.issn.1007-7669.2005.11.010
2005-01-01
Abstract:AIM: To observe the effect of octreotide microspheres for injection on treatment of patients with primary advanced hepotocellular carcinoma.METHODS: Sixty patients with advanced primary hepotocellular carcinoma were divided into two groups with 30 patients in the control group(M 16,F 14;age(48±s 9)a) and other 30 patients in the treatment group(M 18,F 12;age(47±11)a).All patients in both groups were under the supporting therapy,but the patients in the treatment group were further treated combined with octreotide injection 0.1 mg,sc,q8h initially and 2 wk later by octreotide microspheres for injection 20 mg,im,every 4 wk. Patients were followed up monthly and the changes of liver function,T lymphocyte subgroups,serum levels of alpha-fetoprotein(AFP),vascular endothelial growth factor(VEGF),the size of the tumor mass,the accumulative survival rate and the quality of the life were observed.RESULTS: After 3 mo treatment,liver function did not change obviously in the treatment group but with decrease of AFP, VEGF,CD8 and increase of CD3,CD4,CD4/ CD8(P(0.01)).The liver function except albumin impaired,the levels of AFP,VEGF increased but with no obviously changes of CD3,CD4,CD8,CD4/ CD8 in the control group.There were significant difference between the two groups(P0.01).The accumulative survival rate of 3,6,12 mo in the control group were 60 %,33 %,(7 %) and those in the treatment group were 87 %,(67 %),40 %(P0.05 or P0.01).The improvements of the accumulative survival rate and the quality of life were conspicuous in treatment group(P(0.05)).No decreases of the tumor mass and obvious adverse reactions were observed.CONCLUTION: The administration of octreotide microspheres for injection appears to improve the liver function,immunity,survival rate and the quality of life in patients with advanced hepatocellular carcinoma.